PURPOSE: Study of dissolution profiles of nifedipine tablets from different manufacturers to further assess of their equivalence in vitro, as well as study of the dependence of the dissolution profile on the adjuvants composition.
MATERIAL AND METHODS: 3 buffer media with pH 1.2 (hydrochloric acid buffer); 4.5 (acetate buffer); 6.8 (phosphate buffer) was used. The absorptions were observed at 343.
RESULTS: The dissolution profiles of nifedipine tablets from different manufacturers have been studied and have been founded that the percentage of nifedipine release from the sample B is higher than from `Corinfar`, and the percentage of nifedipine release from `Corinfar` is higher than from the sample A. Adjuvants composition of nifedipine tablets have been studied. It is founded that the inclusion of surfactants, solubilizers and emulsifiers into tablets contribute to increasing of active substance release from the dosage form.
CONCLUSIONS: Found that the introduction of surfactants into tablets, solubilizers and emulsifiers help to increase the release of active substance from the dosage form.
Blume H, Schug B. The Biopharmaceutics Classification System (BCS): class III drugs better candidates for BA/BE waiver? Eur J Pharm Sci. 1999; 9: 117-121.
British Pharmacopoeia. – London. The Stationary Office. – 2001. – Vol. 1-2. – 3199 p.
European Pharmacopoeia. – 6th ed. – Strasbourg: European Department for the Quality of Medicines, 2008. – 2416 p.
FDA/CDER. Guidance for industry. Waiver of In vivo bioavailability and bioequivalence studies for immediate- release solid oral dosage forms based on a biopharmaceutics classification system, 2000 Available at http://www.fda.gov/cder/guidance/index.htm (Accessed 19/05/2006).
Guide 42-7.1:2005. Guidelines on Clinical Research. Drugs. Investigation of Bioavailability and Bioequivalence. - Kyiv - 2005. - 19 p.
Hassali M A, Kong D C, Stewart K. Generic drugs: perceptions of consumers in Melbourne, Australia. International Journal of Pharmacy Practice 2005; 13: 257-264.
Health Action International Africa. 30 years of Essential drugs list: Celebrating the gains. Health Action International Africa Network Update 2007; 7: 1-2.
King DR, Kanavos P. Encouraging the use of generic medicines: Implications for transition economies. Croat. Med. J. 2002; 43 (4): 462 - 469.
Kirking DM, Gaither CA, Ascione FJ, Welage LS. Physicians` Individual and Organizational Views on Generic Medications. J Am Pharm Assoc 2001; 41(5): 718-722.
Lindenberg M, Kopp S, Dressman J. Classification of orally administered drugs on the World Health Organization Model list of essential drugs according to the 4. Biopharmaceutics Classification System. Eur J Pharm Biopharm 2004; 58: 265-278..
Somnath S, Sunil C, Bhaswat C. Biowaver monograph for immediate release solid oral dosage forms:- Ofloxacin, Int J Pharm Pharm Sci, 2010; 2(4): 156-161.
State Pharmacopoeia of Ukraine. - 2nd Addition. - Kharkiv - 2008. - 620 p.
The United States Pharmacopoeia, XXIV ed. - United States Pharmacopoeia Convention, Inc, 2000. - 2149 p.
WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series, No. 937, Annex 8. Proposal to waive in vivo bioequivalence requirements for WHO Model
List of Essential Medicines immediate-release, solid oral dosage forms; World Health Organization: Geneva.
Email this article (Login required) 
